Loss of cohesin complex components STAG2 or STAG3 confers resistance to BRAF inhibition in melanoma

Mutation or downregulation of cohesin components confer ERK reactivation and resistance to BRAF or MEK inhibitors in melanoma cells expressing BRAF or NRAS activating mutations.